Sonia Pernas, MD, PhD is a breast medical oncologist with extensive clinical expertise and interest in clinical and translational research. She is the head of the Breast Cancer Unit of the Catalan Institute of Oncology (ICO)-H.U.Bellvige, Barcelona, and its network. She obtained her MD at the University of Barcelona, as well as her PhD in Medicine and Translational Research. She was a Post-Doctoral Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, Harvard Medical School in Boston (MA) from July 2017 through June 2019, where she improved her skills in translational research. She completed the 12-month Harvard Medical School High-Impact Cancer Research (HI-CR) program 2018–2019. Her main research interest is in HER2-positive breast cancer and gene expression. Her other areas of interest include biomarkers of response/resistance to therapy in breast cancer and identifying novel actionable target genes to develop a rational combination of therapies. She has extensive experience in clinical research, being involved in many phases of I-IV breast cancer clinical trials as principal investigator (PI) and co-PI. She is a member of the American Society of Oncology (ASCO), the European Society of Medical Oncology (ESMO), the Spanish Society for Medical Oncology (SEOM) and serves as a member of the Executive Committee and the Scientific Committee of the Spanish cooperative group of SOLTI.